It is very nice to visit Lambda facility and thanks to warm welcome provided by all the teams. I can easily say one of the best CRO I ever visited. People here are wonderful and doing great job

Reputed Client of Israel

Awesome hospitality & fantastic office. All the best!

Reputed Client of Japan

Excellent hospitality and cooperation received throughout the audit. People are knowledgeable and extremely transparent. Looking for long time relation

Reputed Client of Asia

Facility is too good to conduct the BABE studies and adherence to protocol and quality assurance in conducting studies are meeting sponsor expectations and requirements.

Reputed Client of India

Facility is good, people r trained well and know the subject on which they r working. All the best.

Reputed Client of USA

Highly innovative and advanced research centre that possess bright future for the development of the country.

Reputed International Government Body

It is one of the best facility in India for BA/BE

Reputed Regulatory Authority

Lambda is a very professional CRO. All the staff here are experienced and very knowledgeable. I'm grateful for their accommodations and hospitality. The future, if we want to carry out BE study, we will ask Lambda help again.

Reputed Client of Europe

It was a really pleasant meeting with the PV department, and I am looking forward to the next visit.

Reputed Client of Europe

Amazing and best CRO I ever seen

Reputed Client of China



Home / Blog

Overcoming Challenges in a Multicenter Oncology Clinical Trial: Study on Bioequivalence Assessment of Doxorubicin Hydrochloride Liposome Injection

12 Aug 2023

Study Overview

The study aimed to characterize the pharmacokinetic profile and to assess the bioequivalence of Liposomal doxorubicin (TEST) in comparison to RLD (Caelyx® - liposomal doxorubicin), in patients with advanced ovarian cancer or metastatic breast cancer, providing valuable insights into potential advancements in oncology treatments. The study is intended for ANVISA submission, ensuring compliance with the necessary standards.

Study Design

A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) in Patients with Advanced Ovarian Cancer or Metastatic Breast Cancer.

Challenges and Solutions:

Challenges Solutions
Identification of Patients with Advanced Ovarian Cancer or Metastatic Breast Cancer and patient retention for PK study
  • Identification of investigator sites with a substantial patient pool, excellent clinical trial experience, and the requisite infrastructure for the PK study.
Storage of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL:
  • Store between 2°- 8°C (36°-46°F) in a refrigerator. Do not freeze.
  • Freezing or temperature excursion may lead to a change in Liposome formulation and could result in toxic effects.
  • A comprehensive cold chain management to ensure the integrity of the investigational products.
  • A strict protocol to prohibit the use of investigational products in case of any temperature excursion.
IMP Preparation and Administration within Stipulated Timeframe
  • Close oversight of IMP preparation and robust calculations.
  • Utilization of infusion pumps for accurate and timely IMP administration.
  • Conducting in-depth training for the site team on IMP calculations and administration, including on-site demonstrations to ensure proper handling.
Handling of PK samples considering the sensitivity of the molecule, as mishandling can lead to leaching of liposomes.
  • A dedicated, trained, and experienced team of Phlebotomists was deployed to the site to perform all PK sample-related activities, from collection to storage.
  • Continuous oversight of PK sample storage to ensure the preservation and integrity of the sensitive molecules.


  • 74 patients were successfully randomized within a remarkable period of 3 months, demonstrating effective patient enrollment strategies.
  • Efficient trial execution with a timeline of just 6.5 months, starting from the first site initiation visit (SIV) until the last patient's last visit.

Proven Track Record in Oncology Clinical Trials

59 Studies
4238 Patients
876 sites

Leverage Lambda & Novum's extensive experience & proven track record to accelerate your Oncology clinical trials. Get in touch with our team of experts.

Looking for a Globally Proven Research Partner?

Contact Us